| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Cunningham, Janet L., et al.
(author)
-
Predicting disagreement between physicians and patients on depression response and remission
- 2013
-
In: International Clinical Psychopharmacology. - 0268-1315 .- 1473-5857. ; 28:3, s. 134-140
-
Journal article (peer-reviewed)abstract
- Demographic, personality, and disease-related factors all contribute when patients disagree with physicians on the severity of subjective symptoms. This study aims to create a model, on the basis of patient factors at treatment initiation, for longitudinal prediction of disagreement on treatment response and remission in depressed patients. Four hundred patients with major depressive disorder were studied during a clinical drug trial. Repeated assessments with the Montgomery-Asberg Depression Rating Scale (MADRS) and the self-rating version (MADRS-S) were used to indicate response or remission. Factors at baseline and week 2 were tested for inclusion in a model for the prediction of discordance on remission and response between patients and physicians at week 8. The models were then tested, in the same population, at weeks 12, 16, and 24. Model AUCs ranged from 0.71 to 0.74 for week 8. The models that were validated at weeks 12, 16, and 24 indicated stability in the predictive value of the models. The risk for longitudinal disagreement in the evaluation of depression treatment response and remission in clinical practice and drug trials can be predicted using factors at study initiation and at week 2.
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
- Eriksson, Tomas
(author)
-
Anti-androgenic treatment of obsessive-compulsive disorder: an open-label clinical trial of the long-acting gonadotropin-releasing hormone analogue triptorelin.
- 2007
-
In: International Clinical Psychopharmacology. - 1473-5857. ; 22:1, s. 57-61
-
Journal article (peer-reviewed)abstract
- Some case reports have shown that patients suffering from obsessive-compulsive disorder can be effectively treated with anti-androgenic pharmacological agents with various modes of action. The most effective group of such agents is the long-acting analogues of the gonadotropin-releasing hormone. This investigation was undertaken in order to further elucidate the possibility of using such powerful anti-androgenic agents in the treatment of obsessive-compulsive disorder. Six male patients, all suffering from therapy-resistant obsessive-compulsive disorder, were included in a 48 weeks open-label trial of the long-acting GnRH-analogue triptorelin. Every other week, the patients rated the severity of obsessive-compulsive disorder symptoms by means of a visual analogue scale. During the course of the trial, five out of six patients experienced a considerable improvement. The finding gives further support to the contention that anti-androgenic agents are effective in the treatment of obsessive-compulsive disorder.
|
|
| 8. |
- Hagg, S, et al.
(author)
-
Olanzapine and venous thromboembolism
- 2003
-
In: International Clinical Psychopharmacology. - 1473-5857. ; 18:5, s. 299-300
-
Journal article (peer-reviewed)abstract
- Clozapine has recently been associated with venous thromboembolism. The aim of this study was to describe three elderly patients in whom olanzapine therapy was associated with venous thromboembolism. During a 4-month period at the same psychogeriatric clinic, three elderly patients (an 89-year-old male, a 78-year-old male and an 83-year-old female) developed deep venous thrombosis shortly after treatment with olanzapine was initiated. Two of the patients also had symptoms consistent with a diagnosis of pulmonary embolism. None had previously been diagnosed with various thromboembolism. These cases indicate that venous thromboembolism might be associated with the use of olanzapine, at least in geriatric patients. Subjects treated with olanzapine should be monitored clinically for venous thromboembolism to ensure early detection and prompt intervention, and a possible discontinuation of treatment with olanzapine should be considered after a diagnosis of venous thromboembolism. (C) 2003 Lippincott Williams Wilkins.
|
|
| 9. |
|
|
| 10. |
- Hägg, Staffan, 1963-, et al.
(author)
-
High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia
- 2006
-
In: International Clinical Psychopharmacology. - London : Clinical Neuroscience Publishers. - 0268-1315 .- 1473-5857. ; 21:2, s. 93-98
-
Journal article (peer-reviewed)abstract
- Several cardiovascular risk factors have been linked to antipsychotic treatment and cardiovascular mortality is increased in these patients compared to the general population. The full metabolic syndrome (or its components) is associated with an increased risk of cardiovascular disorders. The prevalence of the metabolic syndrome was investigated using a cross-sectional study design in a cohort of 269 patients, aged 20-69 years, with schizophrenia living in Northern Sweden, and was defined according to the criteria of the National Cholesterol Education program. The prevalence of the metabolic syndrome was 34.6% (95% CI = 28.8-40.3) and highest (43%; 95% CI = 32-53) for participants aged 40-49 years. Clozapine treated subjects reached the highest prevalence of the metabolic syndrome (48%; 95% CI = 34-62). The prevalence was similar for men (32.8%; 95% CI = 25.8-39.8) and women (38.0%; 95% CI = 27.9-48.2). Men had a high prevalence of hypertension (49.2%; 95% CI = 41.7-56.6) and women had high prevalence of low high-density lipoprotein cholesterol (40.2%; 95% CI = 30.0-50.4) and abdominal obesity (75.0%; 95% CI = 66.0-84.0). Subjects with the metabolic syndrome had significantly higher mean body mass index (BMI) (P < 0.001), HbA1c (P = 0.002), and fasting serum insulin (P < 0.001) compared to non-metabolic syndrome subject. Subjects with the metabolic syndrome had also significantly more often a positive history of cardiovascular diseases compared to non-metabolic syndrome subjects (25.8% versus 12.5%; P = 0.01). Of all study subjects 36.8% were obese (BMI > 30). These results clearly show that the metabolic syndrome and its components are highly prevalent in patients with schizophrenia. Physicians treating patients with schizophrenia are recommended to monitor the components included in the metabolic syndrome.
|
|
